NCT00381953View on ClinicalTrials.gov

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

July 31, 2006

Conditions
Hepatitis C
Interventions
DRUG

Peginterferon alfa-2a

DRUG

Interferon alfa-2a

DRUG

Ribavirin

Trial Locations (1)

3015 CE

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Foundation for Liver Research

OTHER

NCT00381953 - High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV | Biotech Hunter | Biotech Hunter